143 related articles for article (PubMed ID: 19689297)
1. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression.
Johnson B; Osada T; Clay T; Lyerly H; Morse M
Curr Mol Med; 2009 Aug; 9(6):702-7. PubMed ID: 19689297
[TBL] [Abstract][Full Text] [Related]
2. VEGF as a mediator of tumor-associated immunodeficiency.
Ohm JE; Carbone DP
Immunol Res; 2001; 23(2-3):263-72. PubMed ID: 11444391
[TBL] [Abstract][Full Text] [Related]
3. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
Osada T; Chong G; Tansik R; Hong T; Spector N; Kumar R; Hurwitz HI; Dev I; Nixon AB; Lyerly HK; Clay T; Morse MA
Cancer Immunol Immunother; 2008 Aug; 57(8):1115-24. PubMed ID: 18193223
[TBL] [Abstract][Full Text] [Related]
4. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation.
Dikov MM; Ohm JE; Ray N; Tchekneva EE; Burlison J; Moghanaki D; Nadaf S; Carbone DP
J Immunol; 2005 Jan; 174(1):215-22. PubMed ID: 15611243
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
Johnson BF; Clay TM; Hobeika AC; Lyerly HK; Morse MA
Expert Opin Biol Ther; 2007 Apr; 7(4):449-60. PubMed ID: 17373897
[TBL] [Abstract][Full Text] [Related]
6. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.
Tamura R; Tanaka T; Akasaki Y; Murayama Y; Yoshida K; Sasaki H
Med Oncol; 2019 Nov; 37(1):2. PubMed ID: 31713115
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.
Fricke I; Mirza N; Dupont J; Lockhart C; Jackson A; Lee JH; Sosman JA; Gabrilovich DI
Clin Cancer Res; 2007 Aug; 13(16):4840-8. PubMed ID: 17699863
[TBL] [Abstract][Full Text] [Related]
8. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.
Lissoni P; Malugani F; Bonfanti A; Bucovec R; Secondino S; Brivio F; Ferrari-Bravo A; Ferrante R; Vigoré L; Rovelli F; Mandalà M; Viviani S; Fumagalli L; Gardani GS
J Biol Regul Homeost Agents; 2001; 15(2):140-4. PubMed ID: 11501971
[TBL] [Abstract][Full Text] [Related]
9. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Strauss L; Volland D; Kunkel M; Reichert TE
Med Sci Monit; 2005 Aug; 11(8):BR280-92. PubMed ID: 16049374
[TBL] [Abstract][Full Text] [Related]
10. Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity.
Shi Y; Yu P; Zeng D; Qian F; Lei X; Zhao Y; Tang B; Hao Y; Luo H; Chen J; Tan Y
FEBS J; 2014 Sep; 281(17):3882-93. PubMed ID: 25041128
[TBL] [Abstract][Full Text] [Related]
11. Lymphangiogenesis and anti-tumor immune responses.
Varney ML; Singh S; Backora M; Chen Z; Singh RK
Curr Mol Med; 2009 Aug; 9(6):694-701. PubMed ID: 19689296
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.
Laxmanan S; Robertson SW; Wang E; Lau JS; Briscoe DM; Mukhopadhyay D
Biochem Biophys Res Commun; 2005 Aug; 334(1):193-198. PubMed ID: 16002046
[TBL] [Abstract][Full Text] [Related]
13. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
Gabrilovich DI; Chen HL; Girgis KR; Cunningham HT; Meny GM; Nadaf S; Kavanaugh D; Carbone DP
Nat Med; 1996 Oct; 2(10):1096-103. PubMed ID: 8837607
[TBL] [Abstract][Full Text] [Related]
14. A cancer treatment based on synergy between anti-angiogenic and immune cell therapies.
Soto-Ortiz L; Finley SD
J Theor Biol; 2016 Apr; 394():197-211. PubMed ID: 26826488
[TBL] [Abstract][Full Text] [Related]
15. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property.
Kishuku M; Nishioka Y; Abe S; Kishi J; Ogino H; Aono Y; Azuma M; Kinoshita K; Batmunkh R; Makino H; Ranjan P; Minakuchi K; Sone S
J Immunol; 2009 Dec; 183(12):8176-85. PubMed ID: 20007583
[TBL] [Abstract][Full Text] [Related]
16. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway.
Long J; Hu Z; Xue H; Wang Y; Chen J; Tang F; Zhou J; Liu L; Qiu W; Zhang S; Ouyang Y; Ye Y; Xu G; Li L; Zeng Z
Cancer Sci; 2019 Aug; 110(8):2357-2367. PubMed ID: 31169331
[TBL] [Abstract][Full Text] [Related]
19. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
20. VEGF Requires the Receptor NRP-1 To Inhibit Lipopolysaccharide-Dependent Dendritic Cell Maturation.
Oussa NA; Dahmani A; Gomis M; Richaud M; Andreev E; Navab-Daneshmand AR; Taillefer J; Carli C; Boulet S; Sabbagh L; Labrecque N; Sapieha P; Delisle JS
J Immunol; 2016 Nov; 197(10):3927-3935. PubMed ID: 27815442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
